Brucellosis Vaccine Market
Brucellosis Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type (DNA Vaccine, Subunit Vaccine and Other Vaccine Types), Disease (Viral Diseases, Bacterial Vaccines and Other Diseases), Distribution Channel, Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $239.6 MN |
|
Projected Year Value (2030) |
US $377.4 MN |
|
CAGR (2023 - 2030) |
6.70% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Brucellosis Vaccine Market is accounted for $239.6 million in 2023 and is expected to reach $377.4 million by 2030 growing at a CAGR of 6.70% during the forecast period. The Brucellosis vaccine is a preventive measure against Brucella bacteria, which cause brucellosis—a zoonotic disease affecting animals and humans. The vaccine is primarily administered to livestock such as cattle, goats, and sheep, as these animals are common reservoirs for the bacteria. The vaccine helps control the spread of brucella infections, reducing the risk of transmission to humans through contact with contaminated animal products or direct contact with infected animals.
According to the report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022.
Market Dynamics:
Driver:
Prevalence of brucellosis
With Brucellosis posing substantial health and economic threats globally, particularly in regions with close human-animal interaction, the demand for effective vaccines has risen. Governments, livestock owners, and healthcare authorities are increasingly recognizing the importance of prevention through vaccination to control the spread of Brucellosis. This heightened awareness, coupled with a growing need for sustainable agricultural practices, fuels the expansion of the brucellosis vaccine market as stakeholders actively seek and invest in innovative vaccine solutions to mitigate the impact of this infectious disease.
Restraint:
Antimicrobial treatment options
Antimicrobial treatment options play a crucial role in the restraint of the Brucellosis vaccine market. Antibiotics such as doxycycline and rifampin are essential for managing and treating the infection in humans. This reliance on antimicrobial therapies may hinder the growth of the Brucellosis vaccine market, as effective drugs can provide immediate relief and may reduce the perceived need for preventive vaccination. Additionally, challenges in developing a universally effective brucellosis vaccine further emphasize the significance of antimicrobial treatments in addressing the current burden of the disease.
Opportunity:
Growing livestock industry
As the demand for meat and dairy products rises globally, livestock farmers are keen on ensuring the health and productivity of their herds. Brucellosis can cause reproductive issues in cattle and sheep, leading to economic losses in the industry. The development and widespread adoption of effective Brucellosis vaccines offer a preventive solution, reducing the prevalence of the disease and promoting overall livestock well-being. This presents a lucrative market for vaccine manufacturers, as farmers increasingly prioritize disease management to enhance the sustainability and profitability of their livestock operations.
Threat:
Limited awareness and education
The limited awareness and education threat in the Brucellosis vaccine market arises from insufficient knowledge and understanding among stakeholders, including healthcare professionals and the public. This lack of awareness may hinder the adoption of brucellosis vaccines, leading to lower vaccination rates. Inadequate education about the severity of brucellosis and the benefits of vaccination can contribute to an underestimation of the disease's impact, potentially impeding efforts to control its spread. Addressing this threat requires targeted educational campaigns to enhance awareness among healthcare providers, policymakers, and the general population.
Covid-19 Impact:
The diversion of resources and focus towards combating the global health crisis has led to a slowdown in the development, production, and distribution of brucellosis vaccines. Research and investment priorities have shifted, affecting the overall progress and availability of vaccines for Brucellosis. Additionally, disruptions in supply chains and logistical challenges have further hindered vaccine accessibility. As efforts continue to address COVID-19, the Brucellosis vaccine market faces delays and uncertainties, potentially affecting the control of this bacterial infection in both human and animal populations.
The viral diseases segment is expected to be the largest during the forecast period
The viral diseases segment is experiencing notable growth due to increasing awareness and efforts to combat this bacterial infection. And encompassing innovative research and development targeting Brucella strains, has witnessed a surge in investment and advancements. Furthermore, this growth is driven by a collaborative approach between pharmaceutical companies, research institutions, and governmental initiatives to address the significant public health concern posed by brucellosis.
The animal care centers segment is expected to have the highest CAGR during the forecast period
The Animal Care Centers segment is experiencing notable growth due to increasing awareness and proactive measures taken to control the spread of brucellosis in animals. With a rising emphasis on animal health and welfare, veterinary clinics and care centers are actively incorporating brucellosis vaccination programs into their services. This surge is also driven by regulatory efforts to mitigate the economic and public health impacts of brucellosis. Additionally, as livestock and companion animal owners seek preventive solutions, the demand for brucellosis vaccines within animal care centers is expanding.
Region with largest share:
North America dominated the global market and is expected to retain its position during the forecast period. Potential factors contributing to growth includes increased awareness about brucellosis prevention, rising demand for livestock health management, and government initiatives promoting animal health. The region's advanced veterinary healthcare infrastructure and research capabilities also foster the development and adoption of brucellosis vaccines. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.
Region with highest CAGR:
The Asia Pacific is estimated to grow at a considerable growth rate in the market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China’s increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Increasing demand for dairy and meat products, coupled with a surge in animal husbandry practices, has fueled the need for effective vaccines.
Key players in the market
Some of the key players in Brucellosis Vaccine market include Biogenesis-Bago, Biovet, Boehringer Ingelheim, Calier, Ceva Sante Animale, Colorado Serum, CZ Veterinaria, Hester Biosciences, Indian Immunologicals, Onderstepoort Biological, Qilu, SYVA Laboratorios, Technovax and Zoetis.
Key Developments:
In January 2024, Ceva Santé Animale, acquired US-based Scout Bio, a biotech company focused on pet therapies. The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.
In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.
Vaccine Types Covered:
• DNA Vaccine
• Subunit Vaccine
• Inactivated
• Live Attenuated
• mRNA Vaccines
• Vector Vaccine
• Viral vector vaccines
• Other Vaccine Types
Diseases Covered:
• Viral Diseases
• Bacterial Vaccines
• Allergy Vaccines
• Cancer Vaccines
• Other Diseases
Distribution Channels Covered:
• Hospital & Retail Pharmacies
• Government Suppliers
• Other Distribution Channels
Applications Covered:
• Cattle
• Goat
• Horses
• Sheep
• Swine
• Other Applications
End Users Covered:
• Veterinary Hospitals & Clinics
• Animal Care Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Brucellosis Vaccine Market, By Vaccine Type
5.1 Introduction
5.2 DNA Vaccine
5.3 Subunit Vaccine
5.3.1 Conjugate Vaccines
5.3.2 Recombinant Vaccines
5.3.3 Toxoid Vaccines
5.4 Inactivated
5.5 Live Attenuated
5.6 mRNA Vaccines
5.7 Vector Vaccine
5.8 Viral Vector Vaccines
5.9 Other Vaccine Types
6 Global Brucellosis Vaccine Market, By Disease
6.1 Introduction
6.2 Viral Diseases
6.2.1 Covid-19
6.2.2 Hepatitis
6.2.3 Herpes Zoster
6.2.4 Human Papilloma Virus
6.2.5 Measles, Mumps, and Rubella
6.2.6 Influenza
6.2.7 Rotavirus
6.2.8 Other Viral Diseases
6.3 Bacterial Vaccines
6.3.1 Diphtheria Pertussis Tetanus
6.3.2 Pneumococcal Diseases
6.3.3 Meningococcal Diseases
6.3.4 Other Bacterial Vaccines
6.4 Allergy Vaccines
6.5 Cancer Vaccines
6.6 Other Diseases
7 Global Brucellosis Vaccine Market, By Distribution Channel
7.1 Introduction
7.2 Hospital & Retail Pharmacies
7.3 Government Suppliers
7.4 Other Distribution Channels
8 Global Brucellosis Vaccine Market, By Application
8.1 Introduction
8.2 Cattle
8.3 Goat
8.4 Horses
8.5 Sheep
8.6 Swine
8.7 Other Applications
9 Global Brucellosis Vaccine Market, By End User
9.1 Introduction
9.2 Veterinary Hospitals & Clinics
9.3 Animal Care Centers
9.4 Other End Users
10 Global Brucellosis Vaccine Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Biogenesis-Bago
12.2 Biovet
12.3 Boehringer Ingelheim
12.4 Calier
12.5 Ceva Sante Animale
12.6 Colorado Serum
12.7 CZ Veterinaria
12.8 Hester Biosciences
12.9 Indian Immunologicals
12.10 Onderstepoort Biological
12.11 Qilu
12.12 SYVA Laboratorios
12.13 Technovax
12.14 Zoetis
List of Tables
1 Global Brucellosis Vaccine Market Outlook, By Region (2021-2030) ($MN)
2 Global Brucellosis Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
3 Global Brucellosis Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
4 Global Brucellosis Vaccine Market Outlook, By Subunit Vaccine (2021-2030) ($MN)
5 Global Brucellosis Vaccine Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
6 Global Brucellosis Vaccine Market Outlook, By Recombinant vaccines (2021-2030) ($MN)
7 Global Brucellosis Vaccine Market Outlook, By Toxoid vaccines (2021-2030) ($MN)
8 Global Brucellosis Vaccine Market Outlook, By Inactivated (2021-2030) ($MN)
9 Global Brucellosis Vaccine Market Outlook, By Live Attenuated (2021-2030) ($MN)
10 Global Brucellosis Vaccine Market Outlook, By mRNA Vaccines (2021-2030) ($MN)
11 Global Brucellosis Vaccine Market Outlook, By Vector Vaccine (2021-2030) ($MN)
12 Global Brucellosis Vaccine Market Outlook, By Viral vector vaccines (2021-2030) ($MN)
13 Global Brucellosis Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
14 Global Brucellosis Vaccine Market Outlook, By Disease (2021-2030) ($MN)
15 Global Brucellosis Vaccine Market Outlook, By Viral Diseases (2021-2030) ($MN)
16 Global Brucellosis Vaccine Market Outlook, By Covid-19 (2021-2030) ($MN)
17 Global Brucellosis Vaccine Market Outlook, By Hepatitis (2021-2030) ($MN)
18 Global Brucellosis Vaccine Market Outlook, By Herpes Zoster (2021-2030) ($MN)
19 Global Brucellosis Vaccine Market Outlook, By Human Papilloma Virus (2021-2030) ($MN)
20 Global Brucellosis Vaccine Market Outlook, By Measles, Mumps, and Rubella (2021-2030) ($MN)
21 Global Brucellosis Vaccine Market Outlook, By Influenza (2021-2030) ($MN)
22 Global Brucellosis Vaccine Market Outlook, By Rotavirus (2021-2030) ($MN)
23 Global Brucellosis Vaccine Market Outlook, By Other Viral Diseases (2021-2030) ($MN)
24 Global Brucellosis Vaccine Market Outlook, By Bacterial Vaccines (2021-2030) ($MN)
25 Global Brucellosis Vaccine Market Outlook, By Diphtheria Pertussis Tetanus (2021-2030) ($MN)
26 Global Brucellosis Vaccine Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
27 Global Brucellosis Vaccine Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
28 Global Brucellosis Vaccine Market Outlook, By Other Bacterial Vaccines (2021-2030) ($MN)
29 Global Brucellosis Vaccine Market Outlook, By Allergy Vaccines (2021-2030) ($MN)
30 Global Brucellosis Vaccine Market Outlook, By Cancer Vaccines (2021-2030) ($MN)
31 Global Brucellosis Vaccine Market Outlook, By Other Diseases (2021-2030) ($MN)
32 Global Brucellosis Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
33 Global Brucellosis Vaccine Market Outlook, By Hospital & Retail Pharmacies (2021-2030) ($MN)
34 Global Brucellosis Vaccine Market Outlook, By Government Suppliers (2021-2030) ($MN)
35 Global Brucellosis Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
36 Global Brucellosis Vaccine Market Outlook, By Application (2021-2030) ($MN)
37 Global Brucellosis Vaccine Market Outlook, By Cattle (2021-2030) ($MN)
38 Global Brucellosis Vaccine Market Outlook, By Goat (2021-2030) ($MN)
39 Global Brucellosis Vaccine Market Outlook, By Horses (2021-2030) ($MN)
40 Global Brucellosis Vaccine Market Outlook, By Sheep (2021-2030) ($MN)
41 Global Brucellosis Vaccine Market Outlook, By Swine (2021-2030) ($MN)
42 Global Brucellosis Vaccine Market Outlook, By Other Applications (2021-2030) ($MN)
43 Global Brucellosis Vaccine Market Outlook, By End User (2021-2030) ($MN)
44 Global Brucellosis Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2021-2030) ($MN)
45 Global Brucellosis Vaccine Market Outlook, By Animal Care Centers (2021-2030) ($MN)
46 Global Brucellosis Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
